Matthias W Laschke is an expert in Biochemistry at Saarland University (Germany). As of October 2026, ScienceLeadR ranks Matthias W Laschke in the top 1% of experts worldwide for Tissue Engineering and Cell Engineering. Matthias W Laschke has authored 434 publications, the most recent in 2026. SLR score: 1,352 (community average: 125). How the SLR is computed.

LeadR Profile

Matthias W Laschke Saarland University Germany
1 352 ScienceLeadR Reputation 1352
Network Map

Biochemistry

Subspecialties: Pharmacy - Toxicology - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026

Source: PubMed

Saarland University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 434

Citations

Citations: 12 318 1st author: 65 Last author: 109 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Inflammasome expression patterns during bone regeneration: predictive biomarkers and potential therapeutic targets in non-union formation.
PMID 42819158 — cells, macrophages, inflammasomes, biomarkers, immune system diseases, bone regeneration, therapeutics
Front Immunol20260
Sex-specific differences in pancreatic α-cell function.
PMID 42719565 — cells, islets of langerhans, pancreas, sex, glucagon
Front Endocrinol (Lausanne)20260
Prolonged Ischemia Induces Cellular Stress, Stimulates Extracellular Matrix Remodeling and Compromises the Viability of Human Cancellous Bone Grafts.
PMID 42505371 — cells, genes, polymerase chain reaction, stress, physiological, reoperation, cancellous bone, transplants, extracellular matrix, ischemia, transplantation, gene expression
Cells20260
Boosting the vascularization and regenerative capacity of nanofat by short-term ex vivo pretreatment with erythropoietin.
PMID 42443931 — biomedical research, erythropoietin, tissues, microvessels
J Transl Med20260
The TRPM7 inhibitor carvacrol suppresses angiogenesis and vasculogenic mimicry in triple-negative breast cancer.
PMID 42328442 — cells, triple negative breast neoplasms, growth, breast neoplasms, biological science disciplines, neoplasms, receptors, growth factor, breast, therapeutics, angiogenesis
Int J Biol Sci20261

LeadR Networks

Main global connection map